GC Medical Science (GC MS) said Wednesday that it signed $30 million contracts to export diagnostic kits to 20 countries in Europe, the Middle East, and Asia.

The diagnostic kits, GENEDIA series, can improve the timeliness and efficiency of tests when used together with antibody and molecular test kits.

The product can provide customized solutions for various medical environments, ranging from developed countries with excellent medical infrastructure to developing countries with relatively low access to health services.

The company will seek to win additional export approval for a point-of-care-testing (POCT) molecular diagnostic kit by July.

GC MS said it would have secured four types of diagnostic test kits, two for antibody and two for molecular, including the POCT kit to be approved next month, to increase foreign shipments.

“We expect to have the full lineup of coronavirus-related diagnostic kits, from molecular to immunological diagnosis, and begin to export them in earnest soon, which will contribute significantly to our sales and profits this year,” GC MS CEO Ahn Eun-eok said.